NASDAQ:OPK - Opko Health Stock Price, Forecast & News

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

Opko Health Inc. (NASDAQ:OPK) issued its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. The biotechnology company had revenue of $228.80 million for the quarter, compared to the consensus estimate of $225.40 million. Opko Health had a negative net margin of 30.98% and a negative return on equity of 14.42%. The company's revenue for the quarter was down 8.4% on a year-over-year basis. During the same period last year, the firm earned ($0.05) earnings per share. View Opko Health's Earnings History.

Opko Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Opko Health.

2 Wall Street analysts have issued 12-month price objectives for Opko Health's shares. Their forecasts range from $2.50 to $4.00. On average, they expect Opko Health's share price to reach $3.25 in the next twelve months. This suggests a possible upside of 105.7% from the stock's current price. View Analyst Price Targets for Opko Health.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.

News articles about OPK stock have been trending extremely negative this week, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Opko Health earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Opko Health.

Opko Health saw a increase in short interest in December. As of December 31st, there was short interest totalling 80,770,000 shares, an increase of 5.5% from the December 15th total of 76,560,000 shares. Based on an average daily trading volume, of 5,420,000 shares, the short-interest ratio is presently 14.9 days. Currently, 20.2% of the company's shares are short sold. View Opko Health's Current Options Chain.

Some companies that are related to Opko Health include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), AT&T (T), NVIDIA (NVDA), Bausch Health Companies (BHC) and Novavax (NVAX).

Opko Health's stock is owned by many different of retail and institutional investors. Top institutional investors include RK Asset Management LLC (0.18%), Hollencrest Capital Management (0.01%) and Alpine Global Management LLC (0.01%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

OPK stock was sold by a variety of institutional investors in the last quarter, including RK Asset Management LLC. View Insider Buying and Selling for Opko Health.

OPK stock was acquired by a variety of institutional investors in the last quarter, including Hollencrest Capital Management and Alpine Global Management LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPK stock can currently be purchased for approximately $1.58.

Opko Health has a market capitalization of $1.05 billion and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.View Additional Information About Opko Health.

The official website for Opko Health is http://www.opko.com/.

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]